|  |  | VNIR |  | SWIR | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HSI | Multispectral | Â | HSI | Multispectral | |||||||||||||||||||
186 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | RE | 288 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |||
2016 | Symptomatic (original) | CA (%) | 73 | 60 | 66 | 71 | 72 | 74 | 75 | 75 | 76 | 76 | 70 | 73 | 58 | 60 | 63 | 65 | 66 | 67 | 68 | 69 | 70 |
TPR (%) | 71 | 77 | 71 | 70 | 72 | 72 | 79 | 77 | 77 | 78 | 71 | 70 | 66 | 66 | 66 | 65 | 69 | 66 | 73 | 71 | 74 | ||
FPR (%) | 29 | 37 | 39 | 27 | 26 | 25 | 26 | 26 | 24 | 24 | 30 | 34 | 50 | 40 | 35 | 35 | 34 | 35 | 33 | 30 | 32 | ||
Symptomatic (annotated) | CA (%) | 92 | 68 | 69 | 79 | 84 | 86 | 91 | 90 | 91 | 91 | 82 | 88 | 61 | 85 | 85 | 86 | 86 | 86 | 87 | 87 | 87 | |
TPR (%) | 89 | 69 | 72 | 78 | 83 | 86 | 88 | 88 | 88 | 88 | 86 | 86 | 84 | 71 | 71 | 75 | 76 | 77 | 79 | 81 | 81 | ||
FPR (%) | 0 | 32 | 31 | 19 | 13 | 10 | 6 | 6 | 7 | 6 | 22 | 2 | 48 | 1 | 1 | 3 | 3 | 6 | 4 | 7 | 6 | ||
Pre-symptomatic | CA (%) | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
TPR (%) | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ||
FPR (%) | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ||
2017 | Symptomatic (original) | CA (%) | 70 | 57 | 61 | 66 | 70 | 70 | 71 | 72 | 72 | 73 | 68 | 81 | 62 | 66 | 71 | 74 | 78 | 78 | 79 | 81 | 83 |
TPR (%) | 73 | 80 | 68 | 74 | 74 | 72 | 73 | 78 | 76 | 77 | 72 | 82 | 81 | 77 | 75 | 80 | 84 | 82 | 81 | 84 | 86 | ||
FPR (%) | 32 | 45 | 42 | 39 | 33 | 32 | 32 | 31 | 30 | 30 | 35 | 26 | 44 | 43 | 34 | 31 | 27 | 27 | 23 | 22 | 18 | ||
Symptomatic (annotated) | CA (%) | 90 | 67 | 77 | 73 | 85 | 85 | 86 | 87 | 86 | 89 | 83 | 95 | 65 | 66 | 71 | 77 | 79 | 84 | 87 | 88 | 89 | |
TPR (%) | 90 | 74 | 76 | 81 | 87 | 89 | 89 | 89 | 88 | 91 | 84 | 90 | 77 | 77 | 79 | 78 | 78 | 86 | 86 | 89 | 87 | ||
FPR (%) | 11 | 41 | 22 | 34 | 16 | 17 | 15 | 14 | 15 | 13 | 19 | 6 | 44 | 33 | 31 | 24 | 22 | 16 | 12 | 11 | 11 | ||
Pre-symptomatic | CA (%) | 62 | 53 | 54 | 56 | 59 | 60 | 61 | 62 | 63 | 65 | 59 | 74 | 57 | 62 | 65 | 66 | 67 | 68 | 70 | 71 | 71 | |
TPR (%) | 63 | 38 | 54 | 48 | 61 | 65 | 66 | 60 | 56 | 64 | 56 | 78 | 68 | 71 | 71 | 70 | 77 | 73 | 81 | 77 | 77 | ||
FPR (%) | 35 | 36 | 39 | 36 | 44 | 36 | 32 | 33 | 34 | 31 | 37 | 32 | 52 | 45 | 40 | 41 | 39 | 36 | 36 | 35 | 36 | ||
2018 | Symptomatic (original) | CA (%) | 77 | 63 | 63 | 73 | 75 | 75 | 76 | 76 | 77 | 77 | 68 | 80 | 60 | 60 | 68 | 70 | 72 | 75 | 75 | 77 | 79 |
TPR (%) | 72 | 74 | 66 | 73 | 76 | 74 | 74 | 77 | 77 | 80 | 67 | 74 | 56 | 60 | 64 | 67 | 68 | 74 | 78 | 78 | 82 | ||
FPR (%) | 22 | 41 | 33 | 35 | 25 | 22 | 23 | 25 | 24 | 23 | 31 | 20 | 41 | 37 | 27 | 30 | 28 | 23 | 25 | 21 | 20 | ||
Symptomatic (annotated) | CA (%) | 94 | 71 | 80 | 81 | 82 | 83 | 89 | 90 | 91 | 91 | 84 | 92 | 67 | 73 | 76 | 79 | 85 | 87 | 87 | 88 | 89 | |
TPR (%) | 93 | 71 | 81 | 82 | 82 | 85 | 89 | 89 | 91 | 90 | 83 | 100 | 68 | 65 | 73 | 72 | 83 | 84 | 86 | 87 | 88 | ||
FPR (%) | 5 | 25 | 21 | 20 | 17 | 16 | 11 | 10 | 10 | 10 | 16 | 5 | 28 | 17 | 17 | 16 | 12 | 10 | 12 | 10 | 9 | ||
Pre-symptomatic | CA (%) | 79 | 62 | 66 | 68 | 70 | 71 | 74 | 74 | 75 | 76 | 69 | 86 | 60 | 63 | 65 | 75 | 77 | 78 | 80 | 81 | 82 | |
TPR (%) | 83 | 77 | 73 | 78 | 82 | 82 | 78 | 80 | 81 | 80 | 72 | 87 | 54 | 71 | 63 | 78 | 80 | 80 | 82 | 84 | 79 | ||
FPR (%) | 28 | 41 | 35 | 39 | 24 | 35 | 31 | 31 | 29 | 29 | 34 | 21 | 42 | 40 | 42 | 24 | 22 | 22 | 19 | 17 | 19 |